Kensey Nash Reports Third Quarter Record Revenue and Sales
...eriod. This growth is reflective of the expansion and diversification in our customer base, new product launches and the successful integration of the macropore Biosurgery asset acquisition. There were $1.7 million of new product sales resulting from this acquisition, in addition to substantial increases in sa...Kensey Nash Reports Second Quarter EPS of $0.21 and Revenue of $19.6 Million
...y $400,000 of new product sales resulting from the macropore Biosurgery asset acquisition, and 115% excluding t... of new product sales resulting from the Company's macropore Biosurgery asset acquisition, and 83% excluding th... product revenue related to the acquisition of the macropore Biosurgery assets. The success of the biomaterial ...Kensey Nash Reports First Quarter Fiscal Year 2008 Results
...arter. Orthopaedic sales increased 40% to $6.1 million from $4.4 million in the same period of the prior fiscal year due to new product sales from the macropore asset acquisition that was completed in late fiscal 2007 coupled with strong sales of spine products from our existing customers. Sales of vascular cl...Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results
... most significant customer in this market. The increase in spine product sales included $2.0 million of new product sales resulting from the Company's macropore Biosurgery asset acquisition, completed in May 2007. Sales to Orthovita increased $1.9 million due to strong end user sales of existing products and i...